Ruth Gil-Prieto, Valentín Hernandez-Barrera, Patricia Marín-García, Alba González-Escalada, Ángel Gil-de-Miguel
{"title":"Hospital burden of pneumococcal disease in Spain (2016-2022): A retrospective study.","authors":"Ruth Gil-Prieto, Valentín Hernandez-Barrera, Patricia Marín-García, Alba González-Escalada, Ángel Gil-de-Miguel","doi":"10.1080/21645515.2024.2437915","DOIUrl":null,"url":null,"abstract":"<p><p>Pneumococcal disease is a leading cause of morbidity and mortality worldwide. From 2016 to 2022, 358,603 hospitalized patients were identified as having pneumococcal disease. The overall annual hospitalization rate was 108.9 hospitalizations per 100,000 people, which significantly increased with age, reaching 748.0 hospitalizations per 100,000 among those aged ≥90 years. The hospitalization rates for pneumococcal pneumonia, meningitis, and sepsis were 25.4, 0.7, and 3.5 hospitalizations per 100,000 people, respectively, reaching the highest rates in those ≥90 years of age for pneumococcal pneumonia and sepsis, with 241.6 and 22.0 hospitalizations per 100,000 people, respectively, and in those <1 year of age for meningitis, with 3.4 hospitalizations per 100,000 people. The total number of deaths among all hospitalized pneumococcal infection patients was 51,668, with a total case fatality rate of 14.4%. The case fatality rates for pneumococcal pneumonia, meningitis, and sepsis were 7.9%, 10.6%, and 19.8%, respectively. The case fatality rate increased dramatically with age. Most patients presented with at least one underlying condition. The case fatality rate among patients with at least one comorbidity was significantly higher (<i>p</i> < .05) than that among patients without underlying conditions (16.0% vs. 3.2%, respectively), with a fivefold greater probability of death (OR = 5.7). During this period, the annual cost of hospitalizations for the health system exceeded EUR 383 million. Thus, the use of new broad-spectrum PCVs and improved vaccination protocols for elderly individuals and people with comorbidities could help reduce the high hospital burden of disease and mortality due to pneumococcal infection in our country.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2437915"},"PeriodicalIF":4.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730369/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2024.2437915","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Pneumococcal disease is a leading cause of morbidity and mortality worldwide. From 2016 to 2022, 358,603 hospitalized patients were identified as having pneumococcal disease. The overall annual hospitalization rate was 108.9 hospitalizations per 100,000 people, which significantly increased with age, reaching 748.0 hospitalizations per 100,000 among those aged ≥90 years. The hospitalization rates for pneumococcal pneumonia, meningitis, and sepsis were 25.4, 0.7, and 3.5 hospitalizations per 100,000 people, respectively, reaching the highest rates in those ≥90 years of age for pneumococcal pneumonia and sepsis, with 241.6 and 22.0 hospitalizations per 100,000 people, respectively, and in those <1 year of age for meningitis, with 3.4 hospitalizations per 100,000 people. The total number of deaths among all hospitalized pneumococcal infection patients was 51,668, with a total case fatality rate of 14.4%. The case fatality rates for pneumococcal pneumonia, meningitis, and sepsis were 7.9%, 10.6%, and 19.8%, respectively. The case fatality rate increased dramatically with age. Most patients presented with at least one underlying condition. The case fatality rate among patients with at least one comorbidity was significantly higher (p < .05) than that among patients without underlying conditions (16.0% vs. 3.2%, respectively), with a fivefold greater probability of death (OR = 5.7). During this period, the annual cost of hospitalizations for the health system exceeded EUR 383 million. Thus, the use of new broad-spectrum PCVs and improved vaccination protocols for elderly individuals and people with comorbidities could help reduce the high hospital burden of disease and mortality due to pneumococcal infection in our country.
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.